Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs

Novartis today says its early-stage research group at NIBR is dropping antibacterial and antiviral research programs based in Emeryville, CA. And they’re doing it at a time that drug-resistant strains of bacteria are spreading around the world — an issue that once commanded considerable attention at Novartis.